Biomarker-Directed Targeted Therapy plus Durvalumab in Advanced Non-Small-Cell Lung Cancer: A Phase 2 Umbrella Trial

The Phase II umbrella HUDSON study evaluated rational combination regimens for advanced NSCLC following the failure of anti-PD-(L)1-containing immunotherapy and platinum-doublet therapy.